Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibrin-specific thrombolytic agents.

D Collen1

  • 1Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

Schweizerische Medizinische Wochenschrift
|November 14, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996
Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996
Same author

Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.

Thrombosis and haemostasis·1996
Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996
Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996
Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996
Same journal

Respiratory function test in the case of temporary phrenic nerve contusion, associated with pneumoperitoneum; About the diagnostic value of laparoscopy.

Schweizerische medizinische Wochenschrift·2010
Same journal

Treatment of pulmonary tuberculosis and pleurisy by means of temporary paralysis of the diaphragm, supported by the pneumoperitoneum.

Schweizerische medizinische Wochenschrift·2010
Same journal

Boeck's disease as a tuberculous syndrome.

Schweizerische medizinische Wochenschrift·2010
Same journal

Enteral primary tubercular complexes

Schweizerische medizinische Wochenschrift·2010
Same journal

Tuberculous stenoses of the large bronchi.

Schweizerische medizinische Wochenschrift·2010
Same journal

About the enzyme action.

Schweizerische medizinische Wochenschrift·2010
See all related articles

Human plasma has two activators, prourokinase and tissue-type plasminogen activator (t-PA), that help break down blood clots. Fibrin-specific t-PA shows promise in treating heart attacks with fewer bleeding issues.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • The human plasma fibrinolytic system involves prourokinase (scu-PA) and tissue-type plasminogen activator (t-PA).
  • Plasmin, generated by these activators, breaks down fibrin clots.
  • Inhibitors like alpha 2-antiplasmin regulate fibrinolytic activity.

Purpose of the Study:

  • To review the roles of scu-PA and t-PA in fibrinolysis.
  • To discuss the clinical efficacy and safety of t-PA, particularly in acute myocardial infarction.
  • To explore ongoing research in genetic manipulation for improved t-PA therapeutics.

Main Methods:

  • Literature review of fibrinolytic system components and activators.
  • Analysis of clinical trial data for t-PA and prourokinase.

Related Experiment Videos

  • Discussion of molecular engineering approaches for enhanced t-PA function.

    • Main Results:

    • t-PA exhibits significantly enhanced plasminogen activation in the presence of fibrin.
    • Clinical trials indicate t-PA is well-tolerated with comparable or superior efficacy to streptokinase in myocardial infarction.
    • Prourokinase and combination therapies also show favorable therapeutic outcomes.

    Conclusions:

    • t-PA represents a significant advancement in thrombolytic therapy, especially for acute myocardial infarction.
    • Further research aims to optimize t-PA through genetic modification for enhanced fibrin binding and longer half-life.
    • Prourokinase and combined therapies are promising alternatives in thrombolysis.